Aspisol inhibits tumor growth and induces apoptosis in breast cancer by Zhu, X.G. et al.
Experimental Oncology 30, 289–294, 2008 (December) 289
Breast cancer is the second most common cause 
of cancer death in women [1]. The incidence of breast 
cancer is increasing but current therapy is unable to 
achieve clinical responses in patients with this highly 
invasive metastatic disease. There is a consequent 
need for more effective approaches to prevention and 
treatment of breast cancer. Although many cancers 
initially respond to chemotherapy, resistance often 
develops. Because many breast cancer patients 
treated by standard schemes suffer from undesirable 
side effects [2], studies of new approaches of breast 
cancer treatment should be continued. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
well known to inhibit cyclooxygenase (COX) activity, the 
key enzyme in prostaglandin biosynthesis. However, 
several clinical observations, epidemiological and ex-
perimental studies showed that NSAIDs could be promi-
sing anti-cancer agents. COX-2 overexpression was 
found in breast cancer tissues and it was associated with 
poorer prognosis [3]. Epidemiological studies as well as 
early clinical trials suggest that administration of either 
dual COX-1/COX-2 or selective COX-2 inhibitors may 
reduce the risk of cancer development [4]. Preclinical 
studies also indicated that the inhibition of COX is useful 
in animal models of chemoprevention [5]. Inhibition of 
COX-2 can decrease breast cancer cell motility, invasion 
and matrix metalloproteinase expression [6]. Aspirin has 
been shown to be associated with lower risks of cancer 
incidence and mortality [7]. It was reported recently that 
the use of NSAIDs for 5–9 years for more than 10 years 
reduced the incidence of breast cancer by 21% and 
28%, respectively [8]. Other studies showed that aspirin 
and non-aspirin-NSAIDs contributed to breast cancer 
prevention in the general population [9, 10], and NSAIDs 
induced apoptosis of tumor cells [11–13]. But the mo-
lecular mechanism of NSAIDs-mediated apoptosis is 
still unclear. Preclinical trials are needed to determine 
whether NSAIDs could be used for prevention and/or 
treatment of breast cancer. In spite of the established 
role of COX-2 and NSAIDs in human cancer, little is 
known about the effect and mechanism of NSAIDs in 
the growth control of breast cancer cells. In the present 
investigation, we demonstrated that aspisol reduced 
MDA-MB-231 cells viability, induced their apoptosis by 
increasing the expression of caspase-3 and bax, and 
decreased the expression of COX-2 and bcl-2. Also, we 
demonstrated that aspisol inhibited tumor growth of and 
induced tumor cells apoptosis in C3H mice model. 
MATERIALS AND METHODS
Cell Culture and Drug Treatment. The human 
breast cancer cell line MDA-MB-231 was obtained from 
the American Type Culture Collection (Rockville, MD, 
USA). The cells were grown in Dulbecco’s modified 
eagle medium (DMEM) (GIBCO-BRL, Rockville, USA) 
supplemented with 10% fetal bovine serum (FBS), 
100 U penicillin, 0.1 μg streptomycin and 2 mmol/L 
L-glutamine at 37 °C, with 5% CO2. The cells
 were plated 
in the regular medium for 24 h, which was then replaced 
by either control fresh FBS-free medium or the medium 
containing 1, 5, or 10 mM of aspisol (Fengyaun, Anhui, 
China). Drugs were dissolved directly in DMEM. 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide (MTT) assay. MTT assay was used to 
measure cell viability. Briefly, 2 × 104 MDA-MB-231 cells 
were seeded in 96-well plates in 180 μl of medium, and 
incubated in medium containing different concentrations 
of aspisol (1–10 mM) for 24 h, 48 h and 72 h. 20 μl of MTT 
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(5 mg/ml in PBS) (Sigma, USA) was added to each well, 
and the cells were incubated for an additional 4 h. Blue 
formazans were released from the cells by adding 150 μl 
DMSO with gentle shaking at 37 °C, and absorbance was 
measured at 570 nm using a microplate reader (Bio-Tek 
Instruments, Richmond, USA). Percent of viabile cells 
was defined as the relative absorbance of treated cells 
vs untreated control cells. 
Western blot analysis. Following aspisol treat-
ments, MDA-MB-231 cells were washed twice with 
ice-cold PBS and harvested in sample buffer con-
taining 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 100 mM 
NaCl, 0.5% Triton X-100, 1 mM PMSF, 1 mM sodium 
orthovanadate, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 
and 10 μg/ml aprotinin. Soluble extracts were prepared 
by centrifugation at 12 000 rpm for 30 min at 4 °C. 
Protein concentrations were determined by the Brad-
ford assay. Equivalent amounts of protein (40 μg) for 
each sample were resolved in 12% SDS-PAGE. After 
electrophoresis, proteins were transferred to nitrocel-
lulose membranes and blocked by 5% nonfat milk for 
1h. Antibodies used for Western blot analysis included 
rabbit anti-bcl-2 antibody, rabbit anti-bax antibody 
(Cell Signaling, USA) and mouse anti-аlpha-tubulin 
antibody (Sigma, USA), horseradish peroxidase-con-
jugated secondary antibodies (Santa Cruz, USA). 
Flow cytometry analysis. 24 h after the treatment 
of cells with aspisol poptosis was determined by stai-
ning the cells with annexin V and propidium iodide (PI) 
using apoptosis kit from BD Pharmingen (San Diego, 
USA). The percentage of stained cells in each quadrant 
was quantified using Winmdi 2.9 software.
Immunohistochemistry. To evaluate whether 
aspisol treatment could modify caspase-3 and 
COX-2 expression of, we detected caspases-3 and 
COX-2 expression treated and untreated cells by 
immunohistochemical staining. 2 × 105 cells were 
seeded in triplicates in 6-well plates on coverslips, 
and grown for 24 h. Medium was then replaced with 
media containing aspisol (1–10 mM) and cells were 
grown for the additional 12 h. The cells on coverslips 
were fixed by 4% paraformaldehyde solution, and then 
were dehydrated in alcohol. Endogenous peroxidase 
was blocked by 3% H2O2 in methanol and avidin/biotin 
(Vector Laboratories, Burlingame, CA). The coverslips 
were incubated overnight at 4 °C with 1 : 500 dilutied 
rabbit anti-caspase-3 or rabbit anti-COX-2 (Santa 
Cruz, USA) specific antibody. All appropriate controls 
were made.Immunoreactive complexes were detected 
using tyramide signal amplification (TSA-indirect) and 
visualized with the peroxidase substrate, AEC. Cover-
slips were counter stained with hematoxylin. 
Detection of PGE2 level in culture media. MDA-
MB-231 cells were treated with increasing concentra-
tions of aspisol (1–10 mM). Level of PGE2 released to 
culture media was measured using a PGE2 enzyme im-
munoassay kit (Cayman Chemical, USA). Medium was 
sampled, centrifuged to remove floating cells and im-
mediately frozen at –70 °C before analysis. The PGE2 as-
say was performed according to the manufacturer’s 
instructions. The results were expressed relatively to the 
control. Data presented are the results of at least three 
independent experiments done in triplicates.
Tumor proliferation in C3H mice. Female C3H 
mice were obtained from the Animal Production Area 
of China Medical University. The mice were maintained 
under specific-pathogen-free conditions. We used 
6-week-old mice weighing 18 to 22 g, acclimatized 
for one week before starting the experiments. C3H 
mice spontaneous mammary adenocarcinoma cells 
were injected subcutaneously into forelimb axillas 
of C3H mice (1 × 107 cells per mouse). In 24 h mice 
were treated with vehicle (normal sodium), 5-fluo-
rouracil (5-FU, 10 mg/kg), aspisol (300 mg/kg/day) 
for 4 weeks. Each group comprised of 10 animals. 
The tumor volume (TV) was assessed every 3 days by 
using a calliper measuring of the two major diameters 
by the formula TV = d1 · d22 / 2. After administration of 
the last dose (24 h) mice were killed, the tumors were 
excised, fixed and sliced into 2-mm-thick sections for 
analysis tumor apoptosis with Terminal dUTP nick-end-
labeling assay (TUNEL) assay. The TUNEL assay was 
performed as directed by the manufacturer. Endoge-
nous peroxidase was blocked in scetions, and they 
were treated with 0.25% Triton X-100 in PBS at 50 °C 
for 20 min, and incubated with terminal deoxytrans-
ferase enzyme with biotin dUTP and cobalt ions for 
90 min at 37 °C. Anti-BrdUrd and TUNEL-labeled sec-
tions were visualized with streptavidin peroxidase and 
diaminobenzidine (Dako Corp, Carpinteria, CA), fol-
lowed by hematoxylin staining. Apoptotic nuclei were 
stained dark brown, and normal cell nuclei were blue. 
The animal experiments were approved by the local 
Ethics Committee for Animal Research.
Statistical analysis. All data were expressed 
as mean ± SD and analyzed by one-way of variance 
(ANOVA) or Student’s t-test using SPSS software (ver-
sion 11.0 for Windows). Significance was accepted at 
P < 0.05.
RESULTS
Aspisol inhibited MDA-MB-231 cell viability. 
Our results suggested that treatment with aspisol re-
duced cell viability in dose-dependent manner. Lower 
concentrations of aspisol (5 and 10 mM) significantly 
reduced MDA-MB-231 cells viability in 72 h (Fig. 1).
Aspisol induced dose-dependent apoptosis 
in MDA-MB-231 cells. Following 24 h of drug treat-
ment, induction of apoptosis was observed in the 
MDA-MB-231 cells in a dose-dependent manner 
(Fig. 2). Aspisol at 5 and 10 mM caused the increase 
in apoptotic cells.
COX-2 and caspase-3 expression in MDA-
MB-231 cells. To determine whether the effect of as-
pisol was associated with COX-2 caspase-3 expression 
MDA-MB-231 cells, immunohistochemical analysis was 
performed. It was found that COX-2 was consistently 
expressed by MDA-MB-213 cells, and there was signifi-
cant down-regulation of COX-2 expression upon aspisol 
treatment (Fig. 3). Treatment of MDA-MB-231 cells 
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with 5 and 10 mM aspisol for 12 h caused significant in-
crease in the caspases-3 expression (Fig. 4). Obtained 
results suggested that aspisol-induced apoptosis 
in MDA-MB-231 cells correlated with COX-2 down-
regulation and caspase-3 in these cells.
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Fig. 1. Aspisol inhibits MDA-MB-231 cell viability. MDA-MB-231 cells 
were treated for 24, 48, or 72 h with 0, 1, 5, or 10 mM aspisol. Cells 
viability was determined by MTT analysis. Aspisol significantly 
inhibits the viability of MDA-MB-231 cells in a dose-dependent 
manner. There is a significant difference between control and 
aspisol treatment (*P < 0.05). Experiments were repeated three 
times, with similar results
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Fig. 2. Aspisol induces apoptosis in MDA-MB-231 cells. 
a, control; b, 1 mM aspisol; c, 5 mM aspisol; d, 10 mM aspisol. 
MDA-MB-231 cells were treated for 24 h with 0, 1, 5, or 10 mM 
aspisol. Apoptosis was then determined by flow cytometry. 
Data was analyzed by Student’s t-test. There is a significant 
difference between control and aspisol treatment (*P < 0.05); 
aspisol increased the number of apoptotic MDA-MB-231 cells 
in dose-dependent manner. Experiments were repeated three 
times, with similar results
Aspisol induce the decrease of bcl-2/bax 
ratio in MDA-MB-231 cells. To determine whether 
the effect of aspisol is associated with the changes 
of bcl-2 and bax expression in MDA-MB-231 cells, 
Western blot analysis was performed. It was shown 
that exposure to 10 mM aspisol induced the decrease 
of bcl-2 expression and theincrease of bax expression 
in treated cells. The bcl-2/bax ratio was decreased to 
15.4 ± 5.9% from control (Fig. 5).
Aspisol inhibited COX-2-mediated PGE2 pro-
duction by MDA-MB-231 cells. To determine 
whether COX-2 activity was affected by aspisol 
treatment, PGE2 production was mesuared using 
a PGE2-specific enzymelinked immunosorbent assay. 
The results are presented on Fig. 6. Overall, it was 
shown that aspisol treatment reduced PGE2 secretion 
in MDA-MB-231 cells in a concentration-dependent 
manner (Fig. 6).
Aspisol inhibited tumor growth by inducing 
cancer cells apoptosis in C3H mice. To assess the 
relevance of the in vitro data, we implanted mammary 
adenocarcinoma cells subcutaneously into C3H mice. 
Proliferation of breast cancer xenografts treated with 
aspisol was significantly reduced (Fig. 7). We observed 
an increase in TUNEL positive cells in aspisol-treated 
tumor sections in situ as compared with control tumor 
sections (Fig. 8).
0
20
40
60
80
100
120
0 1 5 10
Aspisol concentration (mM)
CO
X-
2-
po
st
iv
e 
ra
te
 (
%
)
a b
c d
*
*
*
Fig. 3. Aspisol decreases levels of COX-2 in MDA-MB-231 cells. 
a, control; b, 1 mM aspisol; c, 5 mM aspisol; d, 10 mM aspisol. 
MDA-MB-231 cells were treated for 12 h with 0, 1, 5, or 10 mM 
aspisol. COX-2 expression was determined by immunohis-
tochemical analysis with specific antibodies. Data was analyzed 
using one-way ANOVA. *P values represent significant difference 
between vehicle control and aspisol treatment (*P < 0.05). Experi-
ments were repeated three times, with similar results. × 400
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Fig. 4. Aspisol increases levels of caspase-3 in MDA-MB-231 cells. 
a, control; b, 1 mM aspisol; c, 5 mM aspisol; d, 10 mM aspisol. 
MDA-MB-231 cells were treated for 12 h with 0, 1, 5, or 10 mM 
aspisol. Caspase-3 expression was determined by immunohis-
tochemical analysis with specific antibodies. Data was analyzed 
using one-way ANOVA. There is a significant difference between 
vehicle control and aspisol treatment (*P < 0.05). Experiments 
were repeated three times, with similar results. × 400
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Fig. 5. Aspisol decreases levels of bcl-2 and increases bax level in 
MDA-MB-231 cells. After treatment with 0, 1, 5, or 10 mM aspisol 
for 12 h, the protein levels of bcl-2 and bax were examined using 
Western blotting. Blotting of аlpha-tubulin showed equal loading 
of proteins between each lane. Upper panel shows representa-
tive results of three independent experiments. Below panel is bar 
graph of gray intensities of the immunoreactive bands analyzed by 
software. The ratio of bcl-2/bax was shown as fold of control. Data 
were analyzed using one-way ANOVA. There is significant diffe-
rence between vehicle control and aspisol treatment (*P < 0.05). 
Experiments were repeated three times, with similar results
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Fig. 6. Inhibition of production of PGE2 by aspisol. 
MDA-MB-231 cells were cultured for 24 h with the indicated con-
centrations of aspisol. The amounts of PGE2 in the conditioned 
medium were determined by ELISA and expressed relatively to 
the control (*P < 0.05). Experiments were repeated three times, 
with similar results
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Fig. 7. Treatment with aspisol inhibits the growth of xenografts 
in C3H mice. Tumors were measured one time/3 days
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Fig. 8. Effect of aspisol treatment on apoptosis in C3H mice 
tumor models. TUNEL assay comparison of vehicle- (a) and 
aspisol-treated tumors (b) revealed a marked induction of apop-
tosis in tumor cells in C3H mice models. The apoptosis index of 
5% in vehicle-treated tumors increased to 9% in aspisol-treated 
tumors. × 400
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DISCUSSION
COX catalyzes the formation of prostaglandins 
from arachidonic acid. Overexpression of COX leads 
to increased amounts of prostanoids in tumors. Pros-
tanoids affect numerous mechanisms that have been 
implicated in carcinogenesis. PGE2 can stimulate cell 
proliferation and motility while inhibiting immune sur-
veillance and apoptosis [14, 15].
NSAIDs are amongst the most commonly used 
medications worldwide, which can inhibit COX activity. 
They are considered as effective anti-inflammatory, 
anti-pyretic and analgesic drugs, and aspirin is also 
effective in both the primary and secondary prevention 
of cardiovascular diseases. Aspisol, a new generation 
of NSAIDs, inhibits both isoforms of COX (COX-1 and 
COX-2) followed by the decrease of prostanoids 
level. In this study we examined the effect of aspisol 
on human breast cancer MDA-MB-231 cells. The ob-
tained results showed that aspisol strongly induced 
MDA-MB-231 cells apoptosis. 
Apoptosis is important in malignancy for two rea-
sons [16]. First, suppression of apoptosis appears to 
be a critical event in both cancer initiation and pro-
gression. Second, most cytotoxic anticancer agents 
cause tumor regression, at least in part, by inducing 
apoptosis. Induction of tumor cell apoptosis by NSAIDs 
is an important mechanism of their antitumor effects 
[17]. Apoptosis is a tightly regulated process involv-
ing changes in the expression or activities of distinct 
genes [18]. COX inhibitor engages different apoptosis 
pathways in cancer cells, stimulating death receptor 
signa ling, activating caspases and indu cing apoptosis 
via mitochondrial pathway. Evidence suggests that in-
crease in tumorigenic potential by COX-2 overexpres-
sion is associated with resistance to apoptosis. Two 
distinct isoforms of COX exist, the constitutively ex-
pressing COX-1, and the inducible COX-2. COX-1 ex-
presses constitutively in most tissues, whereas the ex-
pression of COX-2 is induced by inflammatory factors, 
hormones and mitogens. COX-1 and COX-2 might 
all be involved in tumorigene sis. Previous study has 
shown that COX-1 and COX-2 specific inhibitiors in 
combined treatment produced the significantly greater 
inhibition as compared to single agents alone [19]. 
M.A. Kern et al. [20] showed that COX-2 inhibition 
induced apoptosis in hepatocellular carcinoma cells. 
Our data revealed that treatment with aspisol caused 
down-regulation of COX-2 in the cells of breast cancer 
cell line MDA-MB-231.
Caspases are aspartate-specific cysteine pro-
teases, which cleave their substrates on the carboxyl 
side of the aspartate residue [21, 22]. Currently at least 
14 different caspases are found, of which two-thirds 
play a role in apoptosis. Caspase-3 is the most widely 
studied enzyme among other caspases. It was de-
monstrated to play a key role in both the death receptor 
pathway, initiated by caspase-8, and the mitochondrial 
pathway, involving caspase-9. Because caspase-3 is 
a critical mediator of apoptosis [21] and correlates with 
apoptosis in breast cancer, it is regarded as a marker 
for prediction of breast cancer cells’ response or resis-
tance to chemotherapeutic agents. We demonstrated 
that aspisol caused up-regulation of caspase-3 in the 
MDA-MB-231 cells, suggesting that up-regulation of 
caspases-3 was involved in aspisol-induced tumor 
cell apoptosis.
Bcl-2 and bax are other important factors regula ting 
apoptosis. Bcl-2 stabilizes mitochondrial memb rane 
integrity by preventing cytochrome c release, and sub-
sequent activation of caspases followed by apoptosis 
[23, 24]. It has been proposed that the anti-apoptotic 
bcl-2 protein and the pro-apoptotic bcl-2 family bax 
proteinare associated with mitochondria-mediated 
apoptosis through regulation of mitochondrial mem-
brane permeability. The ratio of bcl-2 to bax may 
ultimately determine the fate of cells [25]. Liu et al. 
[12] confirmed the relationship between COX-2 and 
bcl-2 family proteins in prostate cancer. Our study 
showed that aspisol treatment significantly reduced 
the bcl-2/bax ratio in MDA-MB-231 cells. We found 
that the levels of COX-2 as well as the bcl-2/bax ratio 
were decreased in MDA-MB-231 cells upon treatment 
with aspisol, suggesting that COX-2 and bcl-2 fami-
ly were involved in aspisol-mediated apoptosis of 
MDA-MB-231 breast cancer cells. Up-regulation of 
bcl-2 by COX-2 may be the mechanism ofthe reduction 
of apoptotic susceptibility in MDA-MB-231 cells. 
In conclusion, it could be assumed that the non-se-
lective COX-2 inhibitor, aspisol, can suppress the via-
bility of MDA-MB-231 cells by induction of apoptosis. 
This effect of aspisol correlated with down-regulation 
of COX-2 and bcl-2 expression and up-regulation of 
caspase-3 expression. Therfore, aspisol should be re-
garded as the potential chemotherapeutic and cancer 
preventive agent in human breast cancer prevention/
treatment.
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АСПИЗОЛ ИНГИБИРУЕТ РОСТ И ВЫЗЫВАЕТ АПОПТОЗ КЛЕТОК 
РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
Нестероидные противовоспалительные препараты ингибируют пролиферацию клеток и вызывают апоптоз во многих 
опухолевых клеточных линиях, что считается важным механизмом их противоопухолевой активности и профилактики 
развития рака. Тем не менее молекулярные механизмы апоптотического действия этих препаратов изучены недостаточно. 
Цель: изучить действие неспецифического ингибитора циклогексиназы-2 (COX-2) — аспизола — на злокачественные клетки 
рака молочной железы in vitro и in vivo. Методы: выживаемоть клеток MDA-MB-231 определяли с помощью MTT-теста. 
Апоптотический индекс измеряли с помощью проточной цитометрии и иммуногистохимическим окрашиванием с анти-
телами против COX-2 и каспазы-3. Экспрессию bcl-2 и bax изучали с помощью Вестерн-блот-анализа. Содержание про-
стагландина E2 (PGE2) в клетках MDA-MB-231 оценивали методом ELISA. In vivo апоптоз опухолевых клеток определяли 
путем выявления разрывов ДНК с помощью концевой дезоксинуклеот-идилтранферазы (метод TUNEL). Результаты: 
показано, что в зависимости от времени инкубации и дозы аспизол угнетал рост клеток MDA-MB-231 in vitro и вызывал 
их апоптоз на фоне повышения экспрессии каспазы-3 и bax, а также снижения экспрессии COX-2 и bcl-2. В условиях 
in vivo аспизол также ингибировал пролиферацию злокачественных клеток рака молочной железы и вызывал их апоптоз. 
Выводы: данные, полученные in vitro и in vivo, свидетельствуют о противоопухолевом эффекте аспизола на клетки рака 
молочной железы, что скорее всего опосредовано его проапоптотическим действием и может быть связано со снижением 
экспрессии COX-2 и bcl-2, а также повышением экспрессии каспазы-3 и bax.
Ключевые слова: аспизол, NSAIDs, апоптоз, COX-2, рак молочной железы.
